N0733: Phase II trial of capecitabine and lapatinib plus or minus cixutumumab in HER2-positive breast cancer

被引：0
|
作者：
Haluska, P.
Reinholz, M. M.
Dueck, A. C.
Linden, H. M.
Lingle, W. L.
Bernath, A. M.
Arbushites, M. C.
Youssoufian, H.
Chen, H. X.
Perez, E. A.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Arizona, Scottsdale, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Geisinger Hlth Syst, Danville, PA USA
[5] GlaxoSmithKline, Collegeville, PA USA
[6] ImClone Syst, Branchburg, NJ USA
[7] NCI, Canc Therapy Evaluat Program, Rockville, MD USA
[8] Mayo Clin Florida, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS129
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
    Kaufman, Bella
    Stein, Steven
    Casey, Michelle A.
    Newstat, Beth O.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 61 - 65
  • [32] Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
    Oliveira, Mafalda
    Garrigos, Laia
    Assaf, Juan David
    Escriva-de-Romani, Santiago
    Saura, Cristina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (09) : 731 - 741
  • [33] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [34] Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial
    Mainwaring, P. N.
    Nguyen, T.
    Price, G.
    Venter, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes
    Takano, Toshimi
    Kimura, Hideharu
    Nishio, Kazuto
    Yamanaka, Takeharu
    Ito, Yoshinori
    Fukuoka, Junya
    Tsurutani, Junji
    Shigeoka, Yasushi
    Uehara, Masahiro
    Sato, Kazuhiko
    Nakamura, Shinichiro
    Nakanishi, Yoichi
    Saeki, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Long-term Complete Response with Lapatinib Plus Capecitabine in a Patient with HER2-Positive Breast Cancer Metastasized to the Pancreas
    Shin, Kichul
    Kim, Jinsu
    Yoon, Seokyoung
    Cho, Eung-Ho
    Jung, Changwon
    Kang, Hye Jin
    EWHA MEDICAL JOURNAL, 2015, 38 (03): : 138 - 143
  • [37] Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)
    Cetin, Bulent
    Benekli, Mustafa
    Turker, Ibrahim
    Koral, Lokman
    Ulas, Arife
    Dane, Faysal
    Oksuzoglu, Berna
    Kaplan, Mehmet Ali
    Koca, Dogan
    Boruban, Cem
    Yilmaz, Burcak
    Sevinc, Alper
    Berk, Veli
    Uncu, Dogan
    Harputluoglu, Hakan
    Coskun, Ugur
    Buyukberber, Suleyman
    JOURNAL OF CHEMOTHERAPY, 2014, 26 (05) : 300 - 305
  • [38] Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial)
    Guarneri, Valentina
    Frassoldati, Antonio
    Piacentini, Federico
    Jovic, Gordana
    Giovannelli, Simona
    Oliva, Cristina
    Conte, PierFranco
    CLINICAL BREAST CANCER, 2008, 8 (02) : 192 - 194
  • [39] Lapatinib Plus Capecitabine in Trastuzumab Pre-Treated HER2-Positive Metastatic Breast Cancer: The Canadian Lapatinib Expanded Access Program Experience
    Chang, J.
    Chia, S.
    Prady, C.
    Haider, K.
    Grenier, D.
    Lopez, P.
    Ghedira, S.
    CANCER RESEARCH, 2010, 70
  • [40] All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer - A phase II study
    Shawky, Hanan
    Tawfik, Hesham
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2014, 26 (04) : 187 - 194
12345